title: Part 4: Interaction between unproven cellular therapies and global medicinal product approval regulatory frameworks.
authors.affiliation: NantKwest, Inc, Culver City, California, USA. ISCT Past Co-Chair, NA LRA Committee 2011-2014. Electronic address: beinc897@gmail.com.
authors.forename: Karen
authors.initials: K
authors.lastname: Nichols
authors.affiliation: St Jude Children's Research Hospital, Memphis, Tennessee, USA. ISCT Past Co-Chair, NA LRA Committee 2011-2014. ISCT North America, Regional Vice-President 2014-2016.
authors.forename: William
authors.initials: W
authors.lastname: Janssen
authors.affiliation: Department of Pathology, University of Melbourne; Cell Therapies Pty Ltd, East Melbourne, Australia, ISCT Australia & New Zealand, Past Regional Vice President 2012-2014 and Chair, ISCT ANZ LRA Committee 2014-2016.
authors.forename: Dominic
authors.initials: D
authors.lastname: Wall
authors.affiliation: Andalusian Initiative for Advanced Therapies, Junta de Andalucía, Sevilla, Spain. Chair, ISCT EU LRA Committee 2014-2016.
authors.forename: Natividad
authors.initials: N
authors.lastname: Cuende
authors.affiliation: Moffitt Cancer Center and Research Institute, Tampa, Florida, USA. Chair, ISCT NA LRA Committee 2014-2016. Co-Editor of the Telegraft.
authors.forename: Deborah
authors.initials: D
authors.lastname: Griffin